INGN in three months: buy, wait or sell?
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
- Buy / Wait / Sell rating
- 3-month target price
- Bear · Base · Bull
- vs. the market
What happened with INGN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Inogen Inc serves patients who need supplemental oxygen over the long term. Its Inogen One and Inogen Rove portable systems concentrate oxygen from surrounding air and deliver it as patients inhale. Equipment sales provide most of its revenue. Home medical equipment providers, distributors and resellers buy its products, while patients can also buy directly in the United States. Outside the United States, Inogen bills distributors and large provider accounts, which handle patient billing and care locally.
Inogen also rents equipment directly to U.S. patients using insurance benefits. It checks coverage, obtains physician paperwork and bills Medicare, private insurers and patients. Medicare supplies most rental revenue, so coverage rules and reimbursement rates matter to this part of the business. Medicare stops regular equipment rental payments before the supplier’s service obligation ends, leaving Inogen responsible for continued oxygen service and equipment upkeep without further equipment rental payments during that period.
A small group of customers contributes a substantial share of revenue, including one particularly large customer. Direct Medicare rentals also require supplier approval, independent accreditation and state licensing; Inogen cannot simply sell a device and bill Medicare without meeting those requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Inogen’s results depend on home oxygen demand, provider purchasing and reimbursement, while its Yuwell collaboration brings new respiratory products and expands Asia-Pacific distribution.
AdaptHealth Corp. supplies home oxygen equipment and ongoing respiratory care to patients who could instead rent oxygen systems directly from Inogen. Watch its Respiratory Health business for signs of demand among the home oxygen patients both companies serve.
Viemed Healthcare, Inc. competes with Inogen for home respiratory patients and physician referrals, providing home oxygen therapy and earning respiratory-equipment revenue mainly through monthly rentals. Its oxygen-therapy news is more directly relevant to Inogen’s oxygen-system business than its broader respiratory revenue, which also includes home ventilation.
AdaptHealth Corp. earningsAHCO
AdaptHealth Corp. serves home-oxygen patients through its Respiratory Health business, and its report will show whether demand among those patients is holding up in a market where some could rent equipment directly from Inogen.
Read AdaptHealth Corp.'s Respiratory Health revenue alongside oxygen-therapy patient or service measures, if reported. Growth in both would point to steady demand among home-oxygen patients served by both companies, supporting the potential pool for Inogen's rentals; weakness in both would point to softer demand in that pool. If revenue grows but oxygen-related measures do not keep pace, the growth may come from other parts of AdaptHealth's business, not the patients Inogen and AdaptHealth share.
Viemed Healthcare, Inc. earningsVMD
Viemed Healthcare, Inc. mainly earns respiratory-equipment revenue from rentals and competes with Inogen for home-oxygen patients and physician referrals, so its report will show whether their overlapping oxygen business is strengthening or softening.
Focus on Viemed Healthcare, Inc.'s oxygen-therapy rental revenue or oxygen-related patient and service measures, if reported, and compare them with its broader respiratory business, which also includes home ventilation. Growth in oxygen measures would show demand in the market the companies share, while also showing that Viemed is serving those patients and competing for them. If oxygen measures weaken while other respiratory services keep the broader business up, the oxygen market overlapping with Inogen's may be softening.
Inogen Inc earningsThis company
Inogen sells oxygen equipment and rents it directly to patients, and this report will show whether both streams support the business without manufacturing and service costs eating away at the economics.
Read product-sales revenue alongside rental revenue, then check gross margin—the share of revenue left after product and service costs. If both streams grow and margin holds, equipment sales and patient rentals are both supporting the business. If either stream weakens, or both fall, while margin narrows, demand, reimbursement or costs are putting pressure on the business; the revenue split shows which stream is under strain.